Document |
Document Title |
WO/2017/206692A1 |
An organic amine salt compound having the general formula (I): An-[Bm+]p. In the formula, An- is anions having -n valence serving as CO2 donors, wherein n = 1, 2, or 3; Bm+ is or contains: ammonium ions and/or organic amine B cations; m ...
|
WO/2017/206693A1 |
An organic amine salt compound having the general formula (I): An-[Bm+]p. In the formula, An- is anions having -n valence serving as CO2 donors, wherein n = 1, 2, or 3; Bm+ is or contains: ammonium ions, hydrazine ions and/or organic ami...
|
WO/2017/204144A1 |
Provided is a method for amidating a hydroxy ester compound at a high chemical selectivity. The amidation reaction method for a hydroxy ester compound comprises, in the presence of a catalyst containing a compound of a transition metal o...
|
WO/2017/195147A1 |
The present invention relates to process for preparation of ledipasvir of formula (1) and its novel intermediates. The process involves reacting a compound of formula (4) with compound of formula (5) to yield a compound of formula (3), d...
|
WO/2017/183723A1 |
The present invention addresses the problem of providing a novel compound having a strong opening action with respect to KCNQ 2-5 channels. Provided is a compound represented by the general formula (I) (in the formula, the definitions of...
|
WO/2017/179018A1 |
There are provided Tissue Transglutaminase (TG2) inhibitor compounds, and compositions and methods of use thereof for the prevention or treatment of a cancer. Compounds of Formula I, and pharmaceutically acceptable salts thereof, are pro...
|
WO/2017/181118A1 |
The present invention provides methods for producing cannabinoid prodrugs. Also described are pharmaceutically acceptable compositions of the prodrugs and a system for the large-scale production of the prodrugs.
|
WO/2017/175238A1 |
: The invention discloses a novel process for highly chemoselective reactions of substituted anilines without any detectable reaction at aromatic amino group. The invention also relates to a novel process for preparation of neostigmine m...
|
WO/2017/172476A1 |
Compounds, compositions, and methods for the treatment of Canavan disease are described.
|
WO/2017/170934A1 |
The present invention pertains to an acetylacetone derivative which is useful in trapping metal elements by complex formation, and a simple and highly versatile synthesis method therefor. More specifically, the present invention pertains...
|
WO/2017/160923A1 |
The present invention relates to formulations of Argan oil and Cannabidiol (CBD). The Formulations of the present invention are useful in treating inflammatory disorders including arthritis. More specifically, the compositions provide sy...
|
WO/2017/155120A1 |
The present invention addresses the problem of providing a long life catalyst which can be produced simply and inexpensively, which exhibits high activity, and in which metal leakage is suppressed. Provided is a catalyst according to sev...
|
WO/2017/137343A1 |
A method for the production of carbamate compounds comprises the steps of: A) reacting an organic primary amine with an organic halogen compound in the presence of a quaternary organic ammonium carbonate and/or bicarbonate, thereby obtai...
|
WO/2017/133620A1 |
The present invention relates to a synthesis process of suvorexant, and a preparation method of novel compounds represented by formulas II, III, IV or V, or a salt or intermediate thereof for preparing the suvorexant. The preparation met...
|
WO/2017/131236A1 |
The present invention relates to the nucleic acid complex expressed by formula 1. Formula 1: (In formula 1, X is an oligonucleotide, L1 and L2 each independently represents a sugar ligand, and S1, S2 and S3 each independently represents ...
|
WO/2017/130156A1 |
The invention relates to compounds of Formula (I), (II), (III) or (IV), salts thereof, pharmaceutical compositions thereof, as well as methods of treating, curing or preventing HIV in subjects.
|
WO/2017/131221A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a and R4b are as defined in the specification, processes for their preparation, pharmaceutical compositions cont...
|
WO/2017/125093A1 |
Disclosed are a hydroquinone compound, a preparation method therefor, and an application in tumour resistance or immunomodulation. The structural formula of the hydroquinone compound is as shown in formula I, wherein: X is C=O or CH2; Y ...
|
WO/2017/105999A1 |
Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, (Formula 1) wherein Z, Q, R1, R2, R3, R4 and m are as defined in the disclosure. Also disclosed are compositions containing the...
|
WO/2017/103278A1 |
The invention relates to novel small molecule compounds having a basic structure as depicted by formula (A), where in particular exemplary embodiments R1 is -OH, R2 is -NO2 and R3 is H, R4 and R5 are H, one of R6 and R7 is selected from ...
|
WO/2017/106138A1 |
Novel compounds of the structural formula I, and the pharmaceutically acceptable salts thereof, are inhibitors of TarO and may be useful in the prevention, treatment and suppression of diseases mediated by TarO, such as bacterial infecti...
|
WO/2017/106279A1 |
Personal care compositions, such as oral care and skin care compositions containing a flavor/perfume system comprising one or more coolants. The pleasant cool sensation provided by a coolant is enhanced in terms of quicker onset, greater...
|
WO/2017/098975A1 |
A method for producing methyl (2Z)-3-(1,1'-biphenyl-4-yl)-2-[(tert-butoxycarbonyl)amino]- prop-2-enoate, comprising the steps of: reacting 4-phenylbenzaldehyde with glycine in the presence of sodium hydroxide or potassium hydroxide to pr...
|
WO/2017/099130A1 |
The purpose of the present invention is to provide: a novel compound which can generate a base and radical upon the irradiation with an active energy ray; a photopolymerization initiator which comprises the novel compound; and a photosen...
|
WO/2017/079821A1 |
There is described herein use of a compound of formula (I) below to make cyclic peptides.
|
WO/2017/059759A1 |
A process is provided for preparation of (R)-N-Boc biphenyl alaninol.It provides a preparation process for a compound outlined as compound 4, which includes these operations: in one of the alcohol solvents, asymmetric hydrogenation of 5 ...
|
WO/2017/057433A1 |
The present invention addresses the problem of developing a novel methodology that provides superior analysis of enantiomers. This problem is solved by means of an enantiomer analysis method comprising (1) to (3) as follows. (1) A mixtur...
|
WO/2017/056832A1 |
Provided is an active-light-sensitive or radiation-sensitive composition that contains (A) a compound having two or more of the structures represented by general formula (1), the compound not having an acid crosslinking group, and (B) a ...
|
WO/2017/049245A2 |
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions fu...
|
WO/2017/046355A1 |
The invention relates to a method for the stereoselective preparation of compounds of formula (IV).
|
WO/2017/043626A1 |
Provided is a method for producing an optically active 4-carbamoyl-2,6-dimethylphenylalanine derivative, which is a compound useful as an intermediate for a medicine, in a simple manner and with high efficiency. 4-carbamoyl-2,6-dimethylb...
|
WO/2017/041139A1 |
The present invention relates to compounds and their uses, in particular, compounds in the form of prodrugs that promote transport of a pharmaceutical agent to the lymphatic system and subsequently enhance release of the parent drug.
|
WO/2017/026944A1 |
An organogelator compound is provided. The organogelator compound has Formula (I): wherein R1, R2, and R3 are independently selected from the group consisting of H, halogen, a substituted or unsubstituted C1-C20 alkyl, a substituted or u...
|
WO/2017/024009A1 |
β-Substituted β-amino acids, β-substituted β-amino acid derivatives, and β-substituted β-amino acid analogs and (bio)isosteres and their use as chemotherapeutic agents are disclosed. The β-substituted β-amino acid derivatives and...
|
WO/2017/018489A1 |
Provided are: a fluorine-containing compound that can obtain a cured product having excellent heat resistance, a superior ability to be released from molds, and a high Abbe number; a curable composition that includes the compound; and a ...
|
WO/2017/006573A1 |
A side chain precursor of paclitaxel and docetaxel is provided at high purity, high yield, and low cost through a method for producing a compound shown by formula (3) using a compound shown by formula (1) as a starting compound. Using th...
|
WO/2016/202808A2 |
The present invention relates to a process for the synthesis of tapentadol intermediates comprising the following route of synthesis: (I) → (II) → (III) → (IV) → (V).
|
WO/2016/202124A1 |
Disclosed are an intermediate, N-methyl-N-methyl formate-2-aminomalononitrile (II), for preparing Riociguat (I) and a preparation method therefor. Preparation steps comprise: 2-aminomalononitrile undergoes an n-methylation reaction to pr...
|
WO/2016/199688A1 |
Tert-Butyl[(2R)-1-(biphenyl-4-yl)-3-hydroxypropan-2-yl]carba
mate can be produced by a step for obtaining a protic acid salt of a compound shown by formula [C]: by reacting a compound shown by formula [A]: with an alcohol shown by formul...
|
WO/2016/192150A1 |
A class of propyl cationic peptide lipids is propyl cationic peptide lipid compounds having a general formula structure as follows. After the propyl cationic peptide lipids are dispersed in water, a cationic liposome with a particle size...
|
WO/2016/193474A1 |
Reaction product containing amidoamine groups, containing one or more species of the general formula (I) (R1-X)p-Z1-(XH)y where p + y = w and w is an integer from 1 to 10, p is an integer from 1 to 10, y is an integer from 0 to 9, and X ...
|
WO/2016/185450A1 |
The present invention relates to an improved process for the preparation of carfilzomib or a pharmaceutically acceptable salt thereof. The present invention also relates to a process for the preparation of amorphous form of carfilzomib.
|
WO/2016/184160A1 |
The present invention relates to a chiral spiro phosphorus-nitrogen-sulphur (P-N-S) tridentate ligand, and a preparation method and application thereof. The P-N-S tridentate ligand is a compound represented by formula I or formula II, a ...
|
WO/2016/180275A1 |
Disclosed are AHU-377 intermediates and a method for preparing AHU-377 and AHU-377 intermediates. The above-mentioned method for preparing AHU-377 uses a chiral glycidyl benzyl ether as the starting raw material. Intermediate compound (3...
|
WO/2016/177761A1 |
The present invention relates to a process for the preparation of an isocyanate compound comprising the steps of: a) Reacting an amine compound A having at least one primary amino group with CO2 and an organotin compound S having at leas...
|
WO/2016/172358A1 |
This invention provides novel indole, indazole, benzimidazole, indoline, quinolone, isoquinoline, and carbazole selective androgen receptor degrader (SARD) compounds, pharmaceutical compositions and uses thereof in treating prostate canc...
|
WO/2016/168059A1 |
This disclosure relates to the field of moiecuies having pesticida i utility against pests in Phyla Arthropoda, Moliusca, and hJematoda, processes to produce such moiecuies, intermediates used In such processes, pesticidai compositions c...
|
WO/2016/168058A1 |
This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions con...
|
WO/2016/150953A1 |
The present invention relates to a process for synthesis of 4,5,6,7- tetrahydroisoxazolo[5,4-c]pyridin-3-ol abbreviated THIP, having the INN name gaboxadol, starting from pyrrolidin-2-one. The process comprises a new direct process to ob...
|
WO/2016/140189A1 |
The purpose of the present invention is to provide a novel method for producing an optically active α-fluoro amino acid compound or a salt thereof. More specifically, the purpose is to produce an α-fluoro amino acid compound or a salt ...
|